Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM by Reinisch, W, Panaccione, R, Bossuyt, P, Baert, F, Armuzzi, A, Travis, S, Danese, S, Sandborn, W, D'Haens, G, Berg, S, Maa, J, Petersson, J, Neimark, E, Robinson, A, Colombel, J

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial by Panaccione, R, Colombel, J, Travis, S, Bossuyt, P, Baert, F, Vaňásek, T, Danalıoğlu, A, Novacek, G, Armuzzi, A, Reinisch, W, Johnson, S, Buessing, M, Neimark, E, Petersson, J, Lee, W, D'Haens, G

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. by Colombel, J, Panaccione, R, Bossuyt, P, Lukas, M, Baert, F, Vanasek, T, Danalioglu, A, Novacek, G, Armuzzi, A, Hébuterne, X, Travis, S, Danese, S, Reinisch, W, Sandborn, W, Rutgeerts, P, Hommes, D, Schreiber, S, Neimark, E, Huang, B, Zhou, Q, Mendez, P, Petersson, J, Wallace, K, Robinson, A, Thakkar, R, D'Haens, G